Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Brian Brown, CPA Appointed CFO of Co-Diagnostics

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

February 23, 2021

Following significant growth in the past year and in anticipation of additional growth in the future, the Company has elected to add additional resources to its financial department. Brian Brown’s previous experience includes CFO, Vice President of Accounting & Investor Relations, and Director of Finance roles for public and private companies.

Brian Brown said, “By virtually every measure, Co-Diagnostics is a true success story. I was immediately drawn to the Company’s vision and ability to run a profitable, well-managed operation during a period of dynamic growth. I look forward to bringing my experience to support the Company in these endeavors.”

Dr. Jesse Montgomery, Ph.D. has also been elevated to the role of Chief Scientific Officer (“CSO”). “Our Company vision, technology platform, and experience are some of our greatest assets, which combined with the groundwork laid by Dr. Satterfield’s vision have all primed the Company for success,” remarked Dr. Montgomery. “I am excited to oversee the Company’s current and future scientific endeavors as Co-Diagnostics continues to progress and innovate in the field of molecular diagnostics.” Dr. Montgomery has been the Company’s Senior Vice President of Biochemistry, following a career that has included research and bioinformatics scientist positions.

Reed Benson, former CFO, will remain with the Company as general counsel, and Dr. Brent Satterfield, founder and former CSO, will continue his involvement with Co-Diagnostics as Head of the Scientific Advisory Board.

Dr. Satterfield commented: “It has been my pleasure to serve as CSO for Co-Diagnostics. In my new capacity as Head of the Scientific Advisory Board, I look forward to exploring new, innovative ways to further strengthen our scientific base, and advancing our ongoing goal of meeting global health challenges by providing affordable, state-of-the-art diagnostic solutions to the world community.”

 

 

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine